Prognostic impact of angiopoietin-2 in multiple myeloma

Pappa, Constantina; Alexandrakis, Michael; Boula, Anna; Thanasia, Aspasia; Konsolas, Ioannis; Alegakis, Athanasios; Tsirakis, George
October 2014
Journal of Cancer Research & Clinical Oncology;Oct2014, Vol. 140 Issue 10, p1801
Academic Journal
Purpose: Angiogenesis is an essential process for the expansion of multiple myeloma (MM). Angiopoietin-2 (Ang-2), Ang-1 and their receptor possess important roles in this procedure. The aim of the study was to measure serum levels of Ang-2 along with known markers of angiogenesis and to estimate their prognostic impact on the survival. Methods: Bone marrow microvascular density (MVD), estimated by CD31, and circulating levels of known angiogenic factors Ang-2, interleukin-6, soluble CD105 and platelet-derived growth factor-AB, measured by ELISA, were measured in 77 newly diagnosed patients with active MM and in 57 of them who responded to chemotherapy. Results: All measured parameters were increased in MM patients, were also increasing in advanced disease and decreased after effective treatment. Ang-2 correlated positively with the other angiogenic factors and MVD. Moreover, Ang-2 values above the median were accompanied by worse survival. Conclusion: Ang-2 correlates strongly with the angiogenic process and its serum levels are importantly prognostic for survival, highlighting the role of angiopoietins pathway in the biology of MM.


Related Articles

  • Serum Level of Lactate Dehydrogenase is a Useful Clinical Marker to Monitor Progressive Multiple Myeloma Diseases: A Case Report. Teke, Hava Üsküdar; Başak, Mustafa; Teke, Deniz; Kanbay, Mehmet // Turkish Journal of Hematology;Mar2014, Vol. 31 Issue 1, p84 

    To follow the progression of multiple myeloma (MM) disease, serum lactate dehydrogenase (LDH) levels are as useful markers as beta-2 microglobulin and monoclonal immunoglobulin. With this study, we have presented a case of a patient with a multiple myeloma which was fulminant course, whose LDH...

  • Bone marrow angiogenesis in myeloma and its precursor disease: a prospective clinical trial. Bhutani, M; Turkbey, B; Tan, E; Kemp, T J; Pinto, L A; Berg, A R; Korde, N; Minter, A R; Weiss, B M; Mena, E; Lindenberg, L; Aras, O; Purdue, M P; Hofmann, J N; Steinberg, S M; Calvo, K R; Choyke, P L; Maric, I; Kurdziel, K; Landgren, O // Leukemia (08876924);Feb2014, Vol. 28 Issue 2, p413 

    A letter to the editor is presented regarding prospective clinical trial on the increased angiogenesis of the bone marrow (BM) in multiple myeloma (MM) and its precursor disease.

  • Anti-Angiogenic Effect of Bortezomib in Patients with Multiple Myeloma. Politou, Marianna; Naresh, Kikkeri; Terpos, Evangelos; Crawley, Danielle; Lampert, Irvin; Apperley, Jane F.; Rahemtulla, Amin // Acta Haematologica;2005, Vol. 114 Issue 3, p170 

    Discusses a study which examined the effect of bortezomib on angiogenesis in bone marrow biopsies and serum samples of patients with multiple myeloma. Information on bortezomib; Assessment of microvessel density in bone marrow trephine biopsies; Interpretation of the research findings.

  • Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy. Kumar, S.; Gertz, M. A.; Dispenzieri, A.; Lacy, M. Q.; Wellik, L. A.; Fonseca, R.; Lust, J. A; Witzig, T. E; Kyle, R. A; Greipp, P. R.; Rajkumar, S. Y. // Bone Marrow Transplantation;Aug2004, Vol. 34 Issue 3, p235 

    Summary:Bone marrow (BM) angiogenesis is increased in multiple myeloma and is an important prognostic factor. However, prior studies were mainly done on patients receiving conventional chemotherapy and there is limited data on its prognostic value in patients undergoing high-dose therapy (HDT)...

  • 11C-Acetate as a new biomarker for PET/CT in patients with multiple myeloma: initial staging and postinduction response assessment. Lin, Chieh; Ho, Chi-Lai; Ng, Shu-Hang; Wang, Po-Nan; Huang, Yenlin; Lin, Yu-Chun; Tang, Tzung-Chih; Tsai, Shu-Fan; Rahmouni, Alain; Yen, Tzu-Chen // European Journal of Nuclear Medicine & Molecular Imaging;Jan2014, Vol. 41 Issue 1, p41 

    Purpose: We investigated the potential value of 11C-acetate (ACT) PET/CT in characterizing multiple myeloma (MM) compared with 18F-FDG PET/CT. Bone marrow histological and whole-body (WB) MRI findings served as the reference standards. Methods: In this prospective study, 15 untreated MM patients...

  • Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Larsen, J T; Kumar, S K; Dispenzieri, A; Kyle, R A; Katzmann, J A; Rajkumar, S V // Leukemia (08876924);Apr2013, Vol. 27 Issue 4, p941 

    A markedly elevated serum free light chain (FLC) ratio may serve as a biomarker for malignant transformation in high-risk smoldering multiple myeloma (SMM) and identify patients who are at imminent risk of progression. We retrospectively studied the predictive value of the serum (FLC) assay in...

  • The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma. Terpos, E.; Dimopoulos, M.-A.; Sezer, O. // Leukemia (08876924);Sep2007, Vol. 21 Issue 9, p1875 

    Immunomodulatory drugs (IMiDs) and bortezomib have been recently used in the management of patients with both newly diagnosed and relapsed/refractory multiple myeloma. Except of their direct anti-myeloma effect, these agents also alter the interactions between myeloma cells and marrow...

  • Assessment of Bone Marrow Fibrosis and Angiogenesis in Monitoring Patients With Multiple Myeloma. Babarović, Emina; Valković, Toni; Štifter, Sanja; Budisavljević, Ivana; Seili-Bekafigo, Irena; Duletić-Načinović, Antica; Lučin, Ksenija; Jonjić, Nives // American Journal of Clinical Pathology;Jun2012, Vol. 137 Issue 6, p871 

    The aim of our study was to emphasize the importance of accurate and standardized techniques for detailed monitoring of the microenvironment in multiple myeloma (MM). Bone marrow fibrosis, angiogenesis, and plasma cell infiltrates in bone marrow biopsy (BMB) samples at the time of diagnosis and...

  • Bone marrow angiogenesis and its correlation with other disease characteristics in multiple myeloma in stage I versus stage II-III. Niemöller, Kathrin; Jakob, Christian; Heider, Ulrike; Zavrski, Ivana; Eucker, Jan; Kaufmann, Olaf; Possinger, Kurt; Sezer, Orhan // Journal of Cancer Research & Clinical Oncology;Apr2003, Vol. 129 Issue 4, p234 

    Purpose. We studied bone marrow angiogenesis in different stages of multiple myeloma according to the Durie and Salmon classification and its correlations with other disease characteristics. Methods. Sixty-five immunohistochemical CD34-stained, paraffin-embedded bone marrow biopsies of multiple...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics